Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y219
UPID:
JAG2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y219; Q9UE17; Q9UE99; Q9UNK8; Q9Y6P9; Q9Y6Q0
Background:
Protein jagged-2, encoded by the gene with accession number Q9Y219, plays a crucial role in Notch signaling, a pathway essential for cell differentiation and development. It is particularly implicated in limb development, suggesting its pivotal role in embryonic morphogenesis.
Therapeutic significance:
Given its involvement in Muscular dystrophy, limb-girdle, autosomal recessive 27, characterized by progressive muscle weakness and potential heart complications, targeting Protein jagged-2 could offer novel therapeutic avenues. Understanding its function and interaction pathways may pave the way for innovative treatments for this debilitating condition.